Leveron&Nexovas
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 2633  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (706 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  Abstract
 »  Materials and Me...
 » Results
 » Discussion
 »  References
 »  Article Tables

 Article Access Statistics
    Viewed311    
    Printed18    
    Emailed0    
    PDF Downloaded4    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
ORIGINAL ARTICLE
Year : 2022  |  Volume : 70  |  Issue : 2  |  Page : 591-595

Evaluation of Neuropatic Pain Features in COVID-19 Patients


1 Department of Neurology, Çanakkale Onsekiz Mart University Faculty of Medicine, Çanakkale, Turkey
2 Department of Family Medicine, Çanakkale Onsekiz Mart University Faculty of Medicine, Çanakkale, Turkey

Date of Submission17-Feb-2021
Date of Decision11-Apr-2021
Date of Acceptance12-Jul-2021
Date of Web Publication3-May-2022

Correspondence Address:
Dr. Erkan Melih Sahin
Çanakkale Onsekiz Mart Üniversitesi Tıp Fakültesi, Aile Hekimliği AD, Barbaros Mah. Terzioğlu Kampüsü, Çanakkale 17020
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.344625

Rights and Permissions

 » Abstract 


Background: Pain is a common complaint in COVID-19 disease. Neurotrophic features of the COVID virus are reported. Neuropathic pain is seen during many viral infections and observed during the COVID-19 pandemic part of the clinical presentations.
Objective: The aim of this is to evaluate neuroptic pain as presenting symptom in COVID-19 patients.
Materials and Methods: In this cross-sectional descriptive study, adult patients (18 years and older) who applied to the COVID Outpatient Clinic completed the demographic data form and the neuropathic pain questionnaire. The patients were divided into positive and negative according to the PCR test results and the presence of neuropathic pain was compared.
Results: In total, 440 participants included in the study. Among 301 who stated to had any complaints, 197 (65.4%) had pain. The intensity of their pain was 5.8 ± 2.4 (0 – no pain and 10 – the most severe pain of life). Neuropathic pain component was present in 29.2% of the patients. Among the first admissions, neuropathic pain component was observed significantly higher in those with positive PCR test (55.0%) than negative ones (23.8%), and the Odd's ratio was calculated as 3.911.
Conclusions: COVID-19 virus is thought to have neuroinvasion and neurotropic effects. In this study, neuropathic pain specifically was evaluated in COVID-19 patients, and the frequency of neuropathic pain was significantly higher in PCR confirmed COVID-19 patients at the onset of the disease.


Keywords: COVID-19, neuropathic pain, PCR test
Key Messages: COVID-19 is a virus with known neurotrophic properties and neurological symptoms and conditions seen with the disease. Neuropathic pain present at the onset of the disease at significantly high rates. Neuropathic pain assessment will be useful in the diagnosis and treatment of patients.


How to cite this article:
Ocak O, Sahin EM. Evaluation of Neuropatic Pain Features in COVID-19 Patients. Neurol India 2022;70:591-5

How to cite this URL:
Ocak O, Sahin EM. Evaluation of Neuropatic Pain Features in COVID-19 Patients. Neurol India [serial online] 2022 [cited 2022 Jun 27];70:591-5. Available from: https://www.neurologyindia.com/text.asp?2022/70/2/591/344625




The International Association for the Study of Pain defines neuropathic pain as the pain result of a primary lesion or dysfunction in the nervous system. In this broad category, clinical pictures, etiology of the primary lesion, and causative neurobiological mechanisms may differ. Neuropathic pain is the most widely accepted term for nonnociceptive pain. The most obvious difference from nociceptive pain is the absence of a continuous nociceptive stimulus.[1] Neuropathic pain is a condition that can have extremely disturbing effects on the patient and may become chronic if it is not treated timely and correctly. Most patients with neuropathic pain complain of throbbing, piercing, or burning pain. Apart from the pain, patients may complain of hyperalgesia (feeling more pain than should be felt with a stimulus that normally causes pain) or allodynia (pain caused by a painless stimulus, for example, feeling pain with cotton touch). Although it is difficult to determine the etiology of neuropathic pain precisely, its presence in patients can be determined by questioning the patients with screening tests.

Many viral infections are known to cause neuropathy and neuropathic pain. Viral genome studies support that peripheral neuropathy develops by immune-mediated mechanisms rather than direct nerve infection and replication of the virus in tissue.[2] Pain is thought to develop as a result of tissue damage as well as inflammation of the peripheral nerves and ganglia.[3] Although cases with neuropathy have been reported during COVID-19, no study has yet been conducted to question neuropathic pain specifically.

In our study, we aimed to determine the frequency of neuropathic pain in COVID-19 patients at the onset of the disease. In this way, the nature of COVID-19 disease can be better understood and the treatment of patients with neuropathic pain can be arranged more successfully.


 » Materials and Methods Top


This is a cross-sectional descriptive study. The data collection phase of the study was carried out between December 21, 2020 and January 22, 2021. All adult patients (18 years and over) who applied to the COVID outpatient clinic were invited to the study. Patients with diseases known to cause neuropathy (diabetes, chronic renal failure, oncological diseases, etc.) and those who used chemotherapy were excluded. Patients who gave consent to participate in the study were asked to fill in the demographic data form and neuropathic pain questionnaire online. Ethics committee approval was obtained for the study from Çanakkale Onsekiz Mart University Ethics Committee for Clinical Studies with decision number 14-18 dated December 09, 2020.

The demographic data form was developed by the researchers for this study. It included questions about the patients' age, gender, marital status, educational status, occupation, employment status, smoking and alcohol habits. Information about the COVID-19 disease processes of the patients was also questioned with this form.

The Neuropathic Pain Questionnaire determines the neuropathic component in patients' pain complaints with 12 questions. The questionnaire score is calculated by multiplying the rates given by the patient for each of the 12 questions by the predetermined coefficients. The presence or absence of neuropathic pain is predicted according to the score. The score of the questionnaire provides a variable that can be used to compare the neuropathic pain component among the patients.[4] Neuropathic Pain Questionnaire, which can be applied without patient contact, was preferred due to concerns about the spread of disease.

The patients were divided into positive (+) and negative (-) according to the PCR test results; admissions were classified as primer and control visits and data analyzed accordingly. Repeated admissions and invalid questionnaires were excluded.

Electroneurological tests and biochemical analyzes were not performed to determine the etiological causes of neuropathic pain. The results to be obtained will only provide observational data on the neuropathic characteristics of pain present in the participants.

After the data were digitalized and corrected, the ordinal data were presented with frequency and percent; the categorical data were presented with mean and standard deviation for descriptive information. The presence of neuropathic pain and neuropathic pain questionnaire scores were analyzed with statistical tests according to the variables of patients' demographic characteristics in COVID-19 disease process. Since the sample size is larger than 30, the normal distribution assumption has been neglected in parametric tests based on the central limit theorem. Analyses were carried out using Chi-square or Fisher's Exact test, Student's t-test, Mann–Whitney U test, and Pearson correlation test in accordance with variable characteristics. Test constants and absolute P values were presented for all analyses; P < 0.05 was accepted as the general significance limit. Odd's ratio of PCR test positivity for the presence of neuropathic pain calculated and presented with 95% confidence intervals.


 » Results Top


The study consisted data of 440 participants, 232 (52.7%) of them were male and 208 (47.3%) were female. Their average age was 40.8 ± 15.4 (minimum 18, maximum 88). Ages were not significantly different between genders (t = 3.094; P = 0.210). In total, 262 of the participants (59.6%) were married, 147 (33.4%) were single, and 31 (7.0%) were widowed or divorced. Six of the participants (1.4%) were illiterate, 2 (0.5%) were literate, 91 (20.7%) were primary school graduates, 35 (8.0%) were secondary school graduates, 97 (22.0%) were high school graduates, 209 (47.5%) were university graduates. Of the participants, 273 (62.0%) were currently working, 91 (20.7%) were not working actively (students, housewives, etc.), 60 (13.6%) were retired, and 16 (3.6%) were unemployed.

Of the participants, 183 (41.6%) were never smoked, 91 (20.7%) were quiters, and 166 (37.7%) were active smokers. In total, 214 of the participants (48.6) were never drinked, 189 (43.0%) were using alcohol in social settings, and 36 (8.2%) were using alcohol regularly.

Primer visits accounted for 62.0%; rest were control visits. In total, 26 of the primer visits (9.5%) consisted of those who remained in isolation at home after contact with Covid-19 patients. Of the control visits, 96 (57.5%) were posttreatment controls and 22 (12.7%) were postisolation controls. PCR tests were positive in 44 (16.5%) of the 266 primer visits and 69 (44.8%) of the 154 control visits. The patients had various complaints in 205 (75.1%) of the primer visits and 96 (57.5%) of the control visits. Among all patients, 132 (31.4%) of them were asymptomatic.

Among the 301 patients who reported having symptoms, 197 (65.4%) had pain in any part of their body. The rate of those with pain was not significantly different for the primer and control visits (X2 = 0.227; P = 0.634). The presence of pain did not differ significantly according to PCR test results (X2 = 0.833; P = 0.361).

The presence of pain did not differ significantly according to gender (X2 = 0.636; P = 0.425). The mean age of those who reported having pain (37.2 ± 13.5) was significantly lower than the age of those who did not (44.7 ± 14.8) (t = 4.442; P < 0.001). Those who stated that they had pain were significantly higher educational status (U = 7536.5; P < 0.001). The frequency of pain complaints differed significantly according to working status (X2 = 15.946; P = 0.001); it was significantly lower in those who did not work (housewife, student, etc.) and retirees.

The presence of pain complaints differed significantly according to smoking status (X2 = 10.429; P = 0.005); it was significantly lower in quitters than never or active smokers. Drinkers had higher rate of pain (71.5%) than nondrinkers (59.2%) (X2 = 4.709; P = 0.030).

The body regions affected by the reported pain complaints are listed in [Table 1]. The most common pain areas are muscles and joints. For the duration of pain, 15 participants reported 1 day, 50 participants 2 days, 49 participants 3 days, 15 participants 4 days, 28 participants 5 days, and 33 participants more than 5 days.
Table 1: Body areas related to pain complaints (187 participants answered)

Click here to view


Their pain was described as intense enough to limit their ability to work, study or do something for at least 1 day by 116 of the participants (61.4%). This did not differ between primer or control visits (X2 = 1.462; P = 0.222) or according to the PCR test result (X2 = 3.657; P = 0.056). When questioned about the relevance of their pain to the period of discomfort that caused their admission to the Covid-19 policlinic, 38 participants stated that their pain increased during this period, 13 participants stated that it reappeared, 116 participants stated that it started in this period, other participants did not respond.

When the patients were asked to rate the intensity of their pain between 0 (no pain) and 10 (the most severe pain in my life), the mean intensity for 196 valid responses was 5.8 ± 2.4. Pain intensity was not significantly different between primer and control visits or according to the PCR test result (t = 1.054; P = 0.293, t = 1.907; P = 0.058, respectively). The average pain intensity reported by women (6.2 ± 2.4) was significantly higher than that of men (5.3 ± 2.4) (t = 2.747; P = 0.007). There was no significant correlation between pain intensity and age (r = 0.011; P = 0.877).

Eight of the participants were excluded from the neuropathic pain assessment because they had diabetes mellitus disease, one had chronic kidney disease, and twowere using chemotherapy. According to 185 valid results, 54 of the participants (29.2%) had the neuropathic component of their pain. The presence of neuropathic pain did not differ significantly according to gender (X2 = 1.889; P = 0.169). The mean ages of those with neuroptic pain were not significantly different from those without (t = 0.254; P = 0.799). The educational status of those with neuropathic pain was significantly lower than those without (U = 2766.5; P = 0.017). The presence of neuropathic pain showed a significant difference in terms of working status (Fisher's exact test X2 = 14.780; P = 0.002); it was significantly higher in nonworkers (housewife, student, etc.). The presence of neuropathic pain did not differ significantly in terms of smoking or alcohol use (X2 = 1.502; P = 0.472, X2 = 0.006; P = 0.939, respectively).

The rate of neuropathic pain component was 28.3% in primer visits and 31.0% in control visits (X2 = 0.139; P = 0.709). The rate of neuropathic pain was significantly higher in those with positive PCR test (48.8%) than those with negative (24.6%) (X2 = 9.000; P = 0.003). The Odd's ratio of PCR test positivity for the presence of neuropathic pain was calculated as 2.921 (95% CI, 1.428–5.975).

When only the primer visits were evaluated, the rate of neuropathic pain was significantly higher in those with positive PCR test (55.0%) than those with negative (23.8%) (X2 = 7.970; P = 0.005). The Odd's ratio of PCR test positivity for the presence of neuropathic pain among the primer admissions was calculated as 3.911 (95% CI, 1.455–10.513). The average scores of the primer visit patients to the questions of the neuropathic pain questionnaire according to PCR test results are given in [Table 2].
Table 2: Average values of pain intensity and Neuropathic Pain Questionnaire items according to PCR results (n=185)

Click here to view



 » Discussion Top


Neuropathic pain is the pain observed directly due to the peripheral or central nervous system dysfunction without stimulation of nociceptors.[5] The problem in neuropathic pain is due to the abnormal processing of perception and is usually seen in people with neurological diseases. Nociceptive pain is a physiological response as a result of tissue damage that will initiate the pain. Unlike neurogenic pain, neuropathic pain does not involve transient disturbances of the peripheral or central nervous system and therefore produces prolonged pain.[6]

Some viruses infecting humans are neurotrophic and can cause neurological complications. HIV infection has effects on the peripheral nervous system, 30–60% of AIDS patients suffer from sensory neuropathy. Neurotropic properties of RNA viruses such as West Nile virus, Hepatitis C virus, HTLV-1, and DNA viruses such as JCV, Epstein–Barr virus, human cytomegalo virus, and mouse adenovirus type 1 have been reported.[7],[8] Although viral infections usually cause ongoing pain during the course of the disease, some viral infections and antiviral responses can cause neuropathies that lead to chronic pain.[9] Direct effects of viruses or early defense responses to viral infection triggering pain hypersensitivity may be possible causes of pain.[10]

COVID-19 virus has still unknowns in terms of its identification and clinical features. Various neurological symptoms including CNS, peripheral nervous system, and skeletal muscle damage have been reported in more than a third of COVID-19 patients.[11] Neurological complications seen in COVID-19 may result from the systemic response to infection or direct effects of the virus. Possible mechanisms effective in the neurological complications of COVID-19 include direct spread of the virus to the nervous system,[12] immune disorder causing persistent fever and high inflammatory markers,[13] and neurological damage caused by hypoxemia, organ failure, and metabolic disorders due to drug effects which is common in severe disease.[14]

COVID-19 patients suffer from neurological symptoms, including peripheral neuropathies. Persistent pain such as neck, back, orofacial, headache, and cervical/lumbar pain may worsen during COVID-19.[15] There were case reports showing peripheral nerve involvement, which may provide evidence that pain is a common symptom during COVID-19 disease. Loss of sense of smell and taste, visual damage, and neuropathic pain are the most commonly reported peripheral nerve symptoms.[16] Pain-related symptoms include myalgia and/or joint pain (arthralgia) (14.8%), sore throat (13.9%), and headache (13.6%).[17]

Peripheral nervous system involvement, including painful neuropathies, has been reported in many patients with COVID-19.[18],[19] Mao et al. reported dysgeusia (5.6%), dysosmia (5.1%), visual disturbances (1.4%), and neuralgia (2.3%) as peripheral nervous system effects.[16] This may be the result of viral invasion of peripheral nerves (neurotropism) or prolonged immobility during severe illness, or both.[20] Pain caused by COVID-19 infection may be due to spinal ACE2's effect on pain sensation and direct or indirect tissue damage.[21] Since COVID-19 virus induces a strong inflammatory response, high cytokine levels (IL-6, IL-10, and TNFα) are present, especially in patients with a moderate or severe disease course.[22] Therefore, pain pathogenesis should include the inflammatory reaction.

COVID-19 has neuroinvasion and neurotrophic effects. Although many studies have been reported about neurological findings of the COVID-19 disease, this is the first to evaluate neuropathic pain. In our study, patients who were admitted with suspicion of COVID-19 disease were evaluated and compared according to PCR test results and neuropathic pain was frequently observed at the onset of the COVID-19 disease by using the Neuropathic Pain Questionnaire, whose validity and reliability were proven to determine the presence of neuropathic pain.

As a limitation of this study, only an observational assessment of the presence of neuropathic pain was made and no conclusion about the etiological origin of neuropathic pain can be reached.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
 » References Top

1.
Treede RD, Jensen TS, Champbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain. Redefinition and a grading system for clinical and research purposes. Neurology 2008;70:1630-5.  Back to cited text no. 1
    
2.
Authier FJ, Bassez G, Payan C, Guillevin L, Pawlotsky JM, Degos JD, et al. Detection of genomic viral RNA in nerve and muscle of patients with HCV neuropathy. Neurology 2003;60:808-12.  Back to cited text no. 2
    
3.
Hardy D. Relief of pain in acute Herpes Zoster by nevre blocks and possible prevention of post-herpetic neuralgia. Can J Anaesth 2005;52:186-90.  Back to cited text no. 3
    
4.
Krause S, Backonja MM. Development of a neuropathic pain questionnaire. Clin J Pain 2003;19:306-14.  Back to cited text no. 4
    
5.
Ziegler D. Treatment of neuropathic pain. In: Gries FA, Cameron NE, Low PA, Ziegler D, editors. Textbook of Diabetic Neuropathy. New York: Georg Thieme Verlag; 2003. p. 211-24.  Back to cited text no. 5
    
6.
Hansson P. Neuropathic pain: Clinical characteristics and diagnostic workup. Eur J Pain 2002;6(Suppl A):47-50.  Back to cited text no. 6
    
7.
Kamerman PR, Moss PJ, Weber J, Wallace VCJ, Rice ASC, Huang W. Pathogenesis of HlV-associated sensory neuropathy: Evidence from in vivo and in vitro experimental models. J Peripher Nerv Syst 2012;17:19-31.  Back to cited text no. 7
    
8.
Koyuncu OO, Hogue IB, Enquist LW. Virus infections in the nervous system. Cell Host Microbe 2013;13:379-93.  Back to cited text no. 8
    
9.
Brizzi KT, Lyons JL. Peripheral nervous system manifestations of infectious diseases. Neurohospitalist 2014;4:230-40.  Back to cited text no. 9
    
10.
Huang L, Ou R, Rabelo de Souza G, Cunha TM, Lemos H, Mohamed E, et al. Virus infections incite pain hypersensitivity by inducing indoleamine 2,3 dioxygenase. PLoS Pathog 2016;12:e1005615.  Back to cited text no. 10
    
11.
Mao L, Wang M, Chen S, He Q, Chang J, Hong C, et al. Neurological manifestations of hospitalized patients with COVID-19 in Vuhan, China: A retrospective case series study. medRxiv 2020. do: 10.1101/2020.02.22.20026500.  Back to cited text no. 11
    
12.
Rao HCY. The emergence of a novel corona virus (SARS-CoV-2) disease and their neuro invasive propensity may affect in COVID-19 patients. J Med Virol 2020;92:786-90.  Back to cited text no. 12
    
13.
Pugin D, Vargas MI, Thieffry C, Schibler M, Grosgurin O, Pugin J, et al. COVID-19-related encephalopathy responsive to high-dose glucocorticoids. Neurology 2020;95:543-6.  Back to cited text no. 13
    
14.
Kanberg N, Ashton NJ, Andersson LM, Yilmaz A, Lindh M, Nilsson S, et al. Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology 2020;95:e1754.  Back to cited text no. 14
    
15.
The British Pain Society. Pain Management during COVID-19 Viral Infection. Available from: https://www.britishpainsociety.org/static/uploads/resources/files/Pain_Management_during_COVID-19_viral_infection.pdf. [Last accessed on 2021 Feb 15].  Back to cited text no. 15
    
16.
Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with Coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020;77:863-90.  Back to cited text no. 16
    
17.
WHO. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Geneva, Switzerland: World Health Organization; 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf.  Back to cited text no. 17
    
18.
Montalvan V, Lee J, Bueso T, de Toledo J, Rivas K. Neurological manifestations of COVID-19 and other corona virus infections: A systematic review. Clin Neurol Neurosurg 2020;194:105921.  Back to cited text no. 18
    
19.
Pleasure SJ, Green AJ, Josephson SA. The spectrum of neurologic disease in the severe acute respiratory syndrome Corona Virus 2 pandemic infection: Neurologists move to the frontlines. JAMA Neurol 2020;77:679-80.  Back to cited text no. 19
    
20.
Li Y-C, Bai W-Z, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020;92:552-5.  Back to cited text no. 20
    
21.
Su S, Cui H, Wang T, Shen X, Ma C. Pain: A potential new label of COVID-19. Brain Behav Immun 2020;87:159-60.  Back to cited text no. 21
    
22.
Pedersen SF, Ho Y-C. SARS-CoV-2: A storm is raging. J Clin Invest 2020;130:2202-5.  Back to cited text no. 22
    



 
 
    Tables

  [Table 1], [Table 2]



 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow